Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Off-Label Debate Between FDA, Industry To Formally Begin After Election

Executive Summary

After years of industry prodding, FDA schedules a two-day public meeting in November to establish direction for off-label regulation, but the agency is already being pulled in multiple directions.


Related Content

Off-Label Compendia Weaknesses Illustrated By Tarceva Evidence Gaps
FDA Taps NIH Veteran Corrigan-Curay To Lead Medical Policy Office
Industry's Off-Label Hearing Priorities Taking Shape
Preapproval Safe Harbor Should Extend 18 Months, Payers And Sponsors Say
FDA's Drug Promotion Advisory Reviews Taking Longer
FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
Off-Label Communications: BIO Lays Ethical Foundation For Change
Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement
US FDA Sets Goal For Biosimilar, Drug Promotion Guidances


Related Companies